prikaz prve stranice dokumenta Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases
  Download
PDF 881.67 KB
Scientific paper - Original scientific paper
Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases
Biomedicines, 12 (2024), 12; 2902. https://doi.org/10.3390/biomedicines12122902
Aurer, Igor; Jakšić, Ozren; Bašić-Kinda, Sandra; Mišura-Jakobac, Karla; Sinčić-Petričević, Jasminka; Novaković-Coha, Sabina; Galušić, Davor; Holik, Hrvoje; Valković, Toni; Županić-Krmek, Dubravka; Hude-Dragičević, Ida; Milunović, Vibor; Pejša, Vlatko

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Aurer, I., Jakšić, O., Bašić Kinda, S., Mišura Jakobac, K., Sinčić Petričević, J., Novaković Coha, S. ... Pejša, V. (2024). Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases. Biomedicines, 12. (12). doi: 10.3390/biomedicines12122902

Aurer, Igor, et al. "Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases." Biomedicines, vol. 12, no. 12, 2024. https://doi.org/10.3390/biomedicines12122902

Aurer, Igor, Ozren Jakšić, Sandra Bašić Kinda, Karla Mišura Jakobac, Jasminka Sinčić Petričević, Sabina Novaković Coha, Davor Galušić, et al. "Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases." Biomedicines 12, no. 12 (2024). https://doi.org/10.3390/biomedicines12122902

Aurer, I., et al. (2024) 'Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases', Biomedicines, 12(12). doi: 10.3390/biomedicines12122902

Aurer I, Jakšić O, Bašić Kinda S, Mišura Jakobac K, Sinčić Petričević J, Novaković Coha S, and sur.. Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases. Biomedicines [Internet]. 2024 December 20 [cited 2024 December 24];12(12). doi: 10.3390/biomedicines12122902

I. Aurer, et al., "Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases", Biomedicines, vol. 12, no. 12, December 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:306597. [Accessed: 24 December 2024]

Metadata
Title (english)Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases
AuthorIgor Aurer
AuthorOzren Jakšić
AuthorSandra Bašić-Kinda
AuthorKarla Mišura-Jakobac
AuthorJasminka Sinčić-Petričević
AuthorSabina Novaković-Coha
AuthorDavor Galušić
AuthorHrvoje Holik
AuthorToni Valković
AuthorDubravka Županić-Krmek
AuthorIda Hude-Dragičević
AuthorVibor Milunović
AuthorVlatko Pejša
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Background/Objectives: Obinutuzumab was approved for front-line treatment of chronic lymphocytic leukemia in combination with chlorambucil pulses administered every 2 wks. Alternative schedules of chlorambucil enable the administration of higher total chlorambucil doses, and have better antileukemia activity. So far, evidence on the feasibility of combining obinutuzumab with alternative chlorambucil schedules is lacking. We performed this retrospective analysis to analyze real life outcomes in chronic lymphocytic leukemia patients receiving a combination of obinutuzumab with different chlorambucil schedules. Methods: This was a retrospective survey performed in order to analyze the feasibility and efficacy of different obinutuzumab and chlorambucil combinations in a real-life setting. Patients receiving this combination as a front-line therapy for chronic lymphocytic leukemia in participating centers, outside of clinical trials, in 2017 and 2018 were included. Results: Seventy-three patients fulfilling entry criteria were identified. Their median age was 76 years, and ranged from 58 to 90 years. The median follow up time was 59 months. The response rate was 89%, with a median progression-free survival time of 27 months, and an overall survival time of 49 months. Chlorambucil was administered as planned in 15 of the 22 (79%) patients treated with chlorambucil pulses every 2 weeks; in 15 of the 42 (34%) patients treated with 7-day courses of chlorambucil administered every 4 weeks; and in 0 of the 10 patients treated with a continuous high dose of chlorambucil (p = 0.002). Changes in treatment schedules were made due to side effects. The progression-free and overall survival rates were similar between the three groups. Conclusions: The combinations of obinutuzumab with more intensive chlorambucil schedules are less feasible, preventing the administration of the intended higher total dose of chlorambucil, and do not improve outcomes in comparison to chlorambucil pulses administered every 2 weeks.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleBiomedicines
Numberingvol. 12, no. 12, 2902
e-ISSN2227-9059
DOIhttps://doi.org/10.3390/biomedicines12122902
URN:NBNurn:nbn:hr:184:306597
Publication2024-12-20
Document URLhttps://www.mdpi.com/2227-9059/12/12/2902
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-12-23 08:03:56